Improving Outcomes Assessment for Microbial Keratitis
Improving Outcomes Assessment for Microbial Keratitis
批准号:
10630922
负责人:
Nakul Shekhawat
金额:
$22.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-06-01 至 2027-03-31
关键词:
AffectAnatomyAnteriorApplied ResearchAreaBiologicalBiometryBlindnessCategoriesCharacteristicsCicatrixClinicalClinical ResearchClinical TrialsClinical assessmentsConduct Clinical TrialsCorneaCorneal DiseasesCorneal UlcerDataDensitometryDiseaseEducational workshopEnrollmentEnvironmentEvidence based treatmentEvolutionEyeglassesFundingFutureGoalsHeterogeneityIndiaIndividualInfectionK-Series Research Career ProgramsKeratitisMeasurementMeasuresMentorsMentorshipMethodologyModalityModelingMonitorMulti-Institutional Clinical TrialMultimodal ImagingNatural HistoryOptical Coherence TomographyOutcomeOutcome AssessmentPatientsPersonsPopulationPrognosisProspective StudiesProspective, cohort studyQuality of lifeReproducibilityResearchSample SizeScientistSeveritiesStatistical ModelsStatistical StudyStratificationStructureSubgroupThinnessTimeTrainingTreatment EfficacyUniversitiesVisionVisualVisual Acuitycareer developmentclinical applicationclinical careclinical practiceclinical trial implementationclinically relevantcohortcomparative efficacycomparison groupcorneal scardensitydesignexperiencefollow-uphealth care settingsimaging modalityimprovedimproved outcomeinnovationinsightmicrobialmicrobial based therapynew technologynovelpatient populationprospectiverandomized trialresearch studyslit lamp imagingsugartomographytreatment responseultrasound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The overarching research goal of this K23 Mentored Career Development Award is to improve outcomes
assessment for microbial keratitis (MK), or infectious corneal ulceration. MK affects 2 million people per year
and causes significant harm to vision and quality of life. Meaningful measurement of MK for clinical and
research purposes remains challenging. Traditional clinical assessments of MK severity and response to
treatment are subjective and imprecise, making it difficult to compare efficacy of treatments in clinical research
studies due to low reproducibility and increased sample size requirements. Prior MK clinical trials have used
outcome metrics such as best spectacle-corrected visual acuity which are not disease-specific and may fail to
capture key information about corneal damage caused by MK. These measurement limitations reduce the
quality and impact of MK research. To date, most large-scale prospective randomized trials in MK have failed
to demonstrate clinically meaningful or statistically significant differences in treatment response between
groups. Single-center MK studies can also lack applicability to other healthcare settings due to differences in
patient characteristics and microbial distributions across populations. Developing more objective, reproducible,
clinically relevant, and generalizable outcome metrics and predictors for MK would enhance the clinical
relevance and statistical power of future multicenter MK studies. New imaging modalities such as Scheimpflug
tomography and anterior segment optical coherence tomography (ASOCT) can provide objective, precise,
reproducible, and clinically relevant assessments of corneal structure, but these modalities have not been
critically evaluated for MK clinical care or research using prospective studies. This application proposes to
conduct a prospective cohort study of MK patients at Johns Hopkins. We will collect detailed clinical and
microbiologic data and perform serial multimodal imaging using slit lamp photography, Scheimpflug
tomography, and ASOCT over 6 months. Aim 1 will compare the reproducibility and concordance of ultrasound
pachymetry, Scheimpflug tomography, and ASOCT for objective quantification of corneal thinning in MK. Aim 2
will evaluate Scheimpflug densitometry as a means of objectively quantifying longitudinal changes in corneal
scar density in MK. Aim 3 will assess whether certain early anatomic or clinical features can improve prediction
of subsequent visual outcomes in MK and whether these predictors are applicable across different MK
populations and infection subgroups, indicating the suitability of these novel outcome metrics for use in
collaborative multicenter clinical trials. This proposal will provide the candidate with the advanced training and
research experience needed to become an expert in clinical trials methodology and an independently funded
clinician-scientist in the field of cornea and external diseases. The candidate proposes a comprehensive
training plan combining rigorous formal coursework, seminars, and workshops in the intellectually rich
environment at Johns Hopkins University; world-class mentorship under Drs. Douglas Jabs, Thomas Lietman,
Elizabeth Sugar, and Albert Jun; immersive experience with ongoing prospective multicenter clinical trials; and
applied research experience. Specific training areas include: (1) advanced clinical trial methodology; (2)
practical clinical trial implementation; (3) advanced biostatistics; (4) clinical and research expertise in microbial
keratitis; and (5) career development as a clinician-scientist. Results from the candidate’s research will be used
to develop a proposal for a R01 or UG1 funded clinical trial that will improve evidence-based treatment for
cornea and external diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving Outcomes Assessment for Microbial Keratitis
-
批准号:10449703
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2022
-
负责人:Nakul Shekhawat
-
依托单位:
海外基金